Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.53 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | OGT | O15294 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644240 | 0.91 | EEF2K (0.66) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL3310158 | 0.91 | EEF2K (0.66) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL5148899 | 0.84 | ATM (0.53) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL13985124 | 0.81 | SLC1A3 (0.56) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL6652039 | 0.81 | SLC1A3 (0.56) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL5149131 | 0.81 | ATM (0.57) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL5150950 | 0.81 | ALDH1A1 (0.53) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL5151530 | 0.81 | POLB (0.56) | EEF2KALDH1A1ATML3MBTL1BDKRB1 | |
| SCHEMBL5155289 | 0.80 | L3MBTL1 (0.61) | EEF2KALDH1A1L3MBTL1BDKRB1 | |
| SCHEMBL5151853 | 0.80 | L3MBTL1 (0.53) | EEF2KALDH1A1ATML3MBTL1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610882-B2 | Affinity for bradykinin receptors; antithrombotics | SANOFI-SYNTHELABO (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2003-04-17 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | EEF2K 2608/4885ALDH1A1 503/4885ATM 4322/4885 |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | EEF2K 2608/4885ALDH1A1 503/4885ATM 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.